Psychemedics Corp Terminates Material Agreement
Ticker: PMDI · Form: 8-K · Filed: Jun 3, 2024 · CIK: 806517
| Field | Detail |
|---|---|
| Company | Psychemedics Corp (PMDI) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.005, $110 thousand, $250 thousand |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Psychemedics terminated a key deal, details TBD.
AI Summary
On May 28, 2024, Psychemedics Corporation reported the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it is classified under Item 1.02 of the 8-K form.
Why It Matters
The termination of a material definitive agreement can signal a significant shift in the company's strategic relationships or operational plans, potentially impacting future revenue or costs.
Risk Assessment
Risk Level: medium — Termination of a material agreement can introduce uncertainty and potential financial repercussions, warranting closer examination.
Key Players & Entities
- Psychemedics Corporation (company) — Registrant
- May 28, 2024 (date) — Date of earliest event reported
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the name or nature of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination?
The earliest event reported is May 28, 2024, which is the date of the report and likely the effective date or date of notification of termination.
Are there any financial implications or penalties associated with this termination?
The filing does not provide details on any financial implications or penalties resulting from the termination.
Does this termination affect any ongoing operations or services provided by Psychemedics Corporation?
The filing does not specify the impact of the termination on the company's ongoing operations or services.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-06-03 16:37:01
Key Financial Figures
- $0.005 — nge on which registered Common stock. $0.005 par value PMD The Nasdaq Stock Market
- $110 thousand — ease to June 30, 2024, is approximately $110 thousand. The Company expects to realize net cos
- $250 thousand — zing of facility costs of approximately $250 thousand for the balance of the original lease t
Filing Documents
- f8k_060324.htm (8-K) — 18KB
- 0001171843-24-003243.txt ( ) — 186KB
- pmd-20240528.xsd (EX-101.SCH) — 3KB
- pmd-20240528_lab.xml (EX-101.LAB) — 33KB
- pmd-20240528_pre.xml (EX-101.PRE) — 22KB
- f8k_060324_htm.xml (XML) — 4KB
02. TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT
ITEM 1.02. TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT On May 28, 2024 Psychemedics corporation (the "Company") entered into a Lease Termination Agreement with Culver City/Hannum, LLC, a California limited liability company ("Landlord") for certain premises located at 5750 Hannum Avenue, Culver City, CA 90230 (the "Lease Termination Agreement"). The Lease Termination Agreement provides that that certain Standard Industrial/Commercial Multi-Tenant Lease - Net dated as of July 29, 2019 by and between the Company and Landlord (as the same may have been amended, the "Lease"), will terminate effective June 30, 2024. The consideration payable by the Company for Landlord's agreement to enter into the Lease Termination Agreement and accelerate the expiration date of the term of the Lease to June 30, 2024, is approximately $110 thousand. The Company expects to realize net cost savings from rightsizing of facility costs of approximately $250 thousand for the balance of the original lease term from what we would otherwise have paid. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PSYCHEMEDICS CORPORATION Dated: June 3, 2024 By: /s/ Daniella Mehalik Daniella Mehalik, Vice President of Finance